Drug Trial News

RSS

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

15 Mar 2021

Henry Ford Cancer Institute launches new initiative to improve minority participation in clinical trials

Henry Ford Cancer Institute is launching the Participatory Action for Access to Clinical Trials (PAACT) project to dramatically improve the representation of the African American community and other minorities in cancer clinical trials.

11 Mar 2021

Nanobody works against all SARS-CoV-2 variants of concern in animal model

Researchers based in Belgium have developed a new antibody drug that is highly successful at neutralizing coronavirus disease 2019 (COVID-19) in Syrian hamsters. The new biologic was administered to the rodents and was found to be equally successful at neutralizing the original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain, and also the new mutant variants, such as the South African and UK strains.

11 Mar 2021

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Researchers from Germany and the US investigated the efficacy of neutralizing antibodies against newer variants using serum and saliva samples obtained from groups of infected, vaccinated (with Pfizer BNT-162b2), and uninfected individuals. The researchers started this study to uncover vaccine-induced immune response and show the efficiency of antibody binding and neutralization in SARS-CoV-2 variants.

10 Mar 2021

Hydroxychloroquine has no effect in treating people with COVID-19, study shows

A year ago, infectious disease doctor Christine Johnston was leading a study on the use of hydroxychloroquine for the treatment of people with COVID-19.

10 Mar 2021

FDA qualifies C-Path’s DIBSS-C for clinical trials

Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces the qualification of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) by the U.S. Food and Drug Administration (FDA).

10 Mar 2021

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

A phase 2 clinical trial is underway at Columbia University and NewYork-Presbyterian to test an investigational gene therapy for dry age-related macular degeneration, a progressive, chronic eye disease with no cure and a leading cause of blindness in the United States.

9 Mar 2021

COVID-19 vaccine candidate approved for human clinical testing

A few days from now the first human will be vaccinated with a Danish vaccine candidate against COVID-19.

9 Mar 2021

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers at the Pitié Salpêtrière Hospital, Department of Virology, Paris, France determined that in BNT162b2-vaccinated participants who received two doses, their sera harbored at least a neutralizing titer against the three SARS-CoV-2 variants.

8 Mar 2021

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

The currently developed vaccines against SARS-CoV-2 include the RBD in their immunogen. With a similar objective, a new study developed an RBD protein-based vaccine candidate against the SARS-CoV-2, using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. The study is published recently in the journal mBio (by the American Society of Microbiology).

8 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Clinical trial launched to test the effectiveness of mouthwash in reducing COVID-19 spread

Researchers at the University of North Carolina at Chapel Hill Adams School of Dentistry have launched a clinical trial to test whether mouthwash can reduce a person's risk of spreading coronavirus.

8 Mar 2021

Rheumatoid arthritis drug improves outcomes in severely ill COVID-19 patients, finds new trial

Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries.

8 Mar 2021

New trend can widen racial disparities in patient enrollment in cancer clinical trials

For the drug approval process in the United States, investigators have been expanding clinical trials to sites outside the country.

8 Mar 2021

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198.

5 Mar 2021

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

5 Mar 2021

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

A new study reports positive outcomes from two new vaccine candidates. The research, led by Axel T. Lehrer from the University of Hawaii at Manoa, studied mice's immune response when administered the CoVaccine HT adjuvant with an insect-cell expressed SARS-CoV-2 spike protein ectodomain.

4 Mar 2021

Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant

Researchers in the United States and South Africa report that the NVX-CoV2373 vaccine from Novavax has proved effective at preventing coronavirus disease (COVID-19) caused by the B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently emerged in South Africa.

4 Mar 2021

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

3 Mar 2021

Study evaluates the effectiveness of methoxyflurane versus standard care for pain management in the ED

Initial management with inhaled methoxyflurane in the emergency department did not achieve the prespecified substantial reduction in pain, but was associated with clinically significant lower pain scores compared to standard therapy.

2 Mar 2021

Previous
1
...
62
63
64
65
66
67
68
...
1149
Next

Drug Trial News

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

Henry Ford Cancer Institute launches new initiative to improve minority participation in clinical trials

Nanobody works against all SARS-CoV-2 variants of concern in animal model

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Hydroxychloroquine has no effect in treating people with COVID-19, study shows

FDA qualifies C-Path’s DIBSS-C for clinical trials

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

COVID-19 vaccine candidate approved for human clinical testing

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Clinical trial launched to test the effectiveness of mouthwash in reducing COVID-19 spread

Rheumatoid arthritis drug improves outcomes in severely ill COVID-19 patients, finds new trial

New trend can widen racial disparities in patient enrollment in cancer clinical trials

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Study evaluates the effectiveness of methoxyflurane versus standard care for pain management in the ED

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News